Is Alkermes’ Schizophrenia Data Enough To Drive Demand?

29 Nov 2018

Alkermes showed that combo pill ALKS 3831 offers a better weight gain profile compared to olanzapine in schizophrenia patients, but analysts differed on whether the benefit would be great enough to drive demand against entrenched generics.

magnetic resonance image (MRI) of the brain human

Alkermes PLC plans to discuss filing its schizophrenia candidate ALKS 3831 for US FDA approval now that it has a second successful Phase III study, but some analysts question whether the olanzapine/samidorphan combination’s better weight-gain profile be enough to drive use of a new branded product in a generic-heavy indication.

ALKS 3831 combines the antipsychotic olanzapine (Eli Lilly & Co.’s Zyprexa and generics) with the novel opioid receptor antagonist samidorphan, which is intended to offset some of the weight-gain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.